Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Laif 900, BAY98-7108 · 1 trial · 1 indication
Definition: Increase of the Hamilton rating scale for depression (HAMD)-17 total score in Phase 2 by \> 5 points compared to Phase 2 baseline, if at the same time a total score of at least 12 is reached.
| Arm | Type | Description |
|---|---|---|
| Hypericum extract STW 3-VI (Laif® 900, BAY98-7108) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Laif® 900, BAY98-7108 | DRUG | 1 x daily, 1 tablet, 900 mg |
| Placebo | DRUG | 1 x daily, 1 tablet, 900 mg |
Inclusion Criteria: Study Phase 1: * Age 18-70 years * Diagnosis according to DSM-IV-TR: 296.32: Outpatients with a mediocre depressive episode requiring treatment for recurrent major depression * At least 5 of the following symptoms must persist for 2 weeks, with at least one of the main symptoms...
Laif 900, also known as BAY98-7108, is an investigational drug being studied for the treatment of moderate depressive episodes, which is a form of major depression. It is a small molecule developed by Bayer AG and is currently in Phase 3 clinical development.
Laif 900 is based on Hypericum extract, a drug derived from the plant St. John's Wort. The specific molecular target of Laif 900 has not been disclosed in available clinical trial information.
Laif 900 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market.
Laif 900 is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy.
Laif 900 has been studied in a Phase 3 clinical trial with the identifier NCT04315597. This trial, titled "Study to Learn About Relapse Prevention of Hypericumextract in Outpatients Suffering From Moderate Depressive Episodes," was a randomized, double-blind, placebo-controlled study that enrolled 398 participants aged 18 years and older. The trial has been completed.
Yes, Laif 900 is also known as BAY98-7108. Both names refer to the same investigational drug being developed by Bayer AG for the treatment of moderate depressive episodes.